dc.contributor.author | Minnee, H | |
dc.contributor.author | Rack, JGM | |
dc.contributor.author | van der Marel, GA | |
dc.contributor.author | Overkleeft, HS | |
dc.contributor.author | Codée, JDC | |
dc.contributor.author | Ahel, I | |
dc.contributor.author | Filippov, D | |
dc.date.accessioned | 2023-10-31T14:27:28Z | |
dc.date.issued | 2023-10-30 | |
dc.date.updated | 2023-10-31T12:01:24Z | |
dc.description.abstract | The transfer of an adenosine diphosphate (ADP) ribose moiety to a nucleophilic side chain by consumption of nicotinamide adenine dinucleotide is referred to as ADP-ribosylation, which allows for the spatiotemporal regulation of vital processes such as apoptosis and DNA repair. Recent mass-spectrometry based analyses of the ‘ADP-ribosylome’ have identified histidine as ADP-ribose acceptor site. In order to study this modification, a fully synthetic strategy towards α-configured N(τ)- and N(π)-ADP-ribosylated histidine-containing peptides has been developed. Ribofuranosylated histidine building blocks were obtained via Mukaiyama-type glycosylation and the building blocks were integrated into an ADP-ribosylome derived peptide sequence using fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase peptide synthesis. On-resin installation of the ADP moiety was achieved using phosphoramidite chemistry, and global deprotection provided the desired ADP-ribosylated oligopeptides. The stability under various chemical conditions and resistance against (ADP-ribosyl) hydrolase-mediated degradation has been investigated to reveal that the constructs are stable under various chemical conditions and non-degradable by any of the known ADP-ribosylhydrolases. | en_GB |
dc.description.sponsorship | Medical Research Council (MRC) | en_GB |
dc.description.sponsorship | National Institute for Health and Care Research (NIHR) | en_GB |
dc.description.sponsorship | Wellcome Trust | en_GB |
dc.description.sponsorship | Biotechnology and Biological Sciences Research Council (BBSRC) | en_GB |
dc.description.sponsorship | Cancer Research UK | en_GB |
dc.description.sponsorship | Ovarian Cancer Research Alliance | en_GB |
dc.identifier.citation | Article e202313317 | en_GB |
dc.identifier.doi | https://doi.org/10.1002/ange.202313317 | |
dc.identifier.grantnumber | MR/N006364/2 | en_GB |
dc.identifier.grantnumber | MR/V033417/1 | en_GB |
dc.identifier.grantnumber | MR/X007472/1 | en_GB |
dc.identifier.grantnumber | 210634 | en_GB |
dc.identifier.grantnumber | 223107 | en_GB |
dc.identifier.grantnumber | BB/R007195/1 | en_GB |
dc.identifier.grantnumber | BB/W016613/1 | en_GB |
dc.identifier.grantnumber | C35050/A22284 | en_GB |
dc.identifier.grantnumber | 813369 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/134369 | |
dc.identifier | ORCID: 0000-0001-8341-6439 (Rack, Johannes GM) | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley / Gesellschaft Deutscher Chemiker | en_GB |
dc.rights.embargoreason | Under embargo until 30 October 2024 in compliance with publisher policy | |
dc.rights | © 2023 Wiley | en_GB |
dc.subject | ADP-ribosylation | en_GB |
dc.subject | Glycosylation | en_GB |
dc.subject | Histidine | en_GB |
dc.subject | Peptides | en_GB |
dc.subject | Solid-phase synthesis | en_GB |
dc.title | Solid‐Phase Synthesis and Biological Evaluation of Peptides ADP‐ribosylated at Histidine | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-10-31T14:27:28Z | |
dc.identifier.issn | 0044-8249 | |
dc.description | This is the author accepted manuscript. The final version is available from Wiley via the DOI in this record | en_GB |
dc.identifier.eissn | 1521-3757 | |
dc.identifier.journal | Angewandte Chemie | en_GB |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2023-10-30 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-10-31T14:22:49Z | |
refterms.versionFCD | AM | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2023-10-30 | |